Zusammenfassung
Anliegen In dieser Kasuistik werden die Entwicklung einer γ-Hydroxybutyrat-Abhängigkeit und
deren stationäre Entgiftung vor dem Hintergrund einer primär bestehenden Alkoholabhängigkeit
beschrieben. Methode Es werden Ausgangslage, psychopathologischer Befund und Verlauf der Entgiftung beschrieben.
Ergebnisse / Schlussfolgerung Die kombinierte Entgiftung von GHB und Alkohol erfolgte mit einem Diazepam-Reduktionsschema.
Die für die Alkoholentgiftung etablierten Entzugsskalen waren mit Einschränkungen
hilfreich. Bei dem Patienten liegt nach ICD-10 eine Polytoxikomanie vor.
Abstract
Objective γ-Hydroxybutyrat (GHB) is used medically for narcolepsy and as a narcotic. It is
also a rare illegal drug. In this case report the development of a GHB-dependency
against the background of a primary alcohol dependency is described. Methods Based on established alcohol withdrawal scales (AWSS by Wetterling, CIWA) and neuropsychological
testing procedures (CGI, GAF, SKID-II, PISQ, analog-scale for Craving), the initial
situation, the development of psychopathological findings, and the course of detoxification
were shown. Results / Conclusion The combined detoxication of GHB and alcohol was successfully finished by a reduction
schedule of diazepam. Withdrawal-assessment scales for alcohol were helpful, but show
limitations for GHB-withdrawal symptoms. The patient suffers, according to ICD-10,
from a multiple drug dependence (alcohol, GHB, abstinence from amphetamines). Symptoms
of insomnia, major depression, and generalized anxiety disorder can be associated
with the use of GHB.
Schlüsselwörter
GHB - Abhängigkeit - Entgiftung - Alkohol - Entgiftung
Key words
GHB - dependence - detoxification - alcohol - withdrawal
Literatur
1 Die Drogenbeauftragte der Bundesregierung .Drogen – und Suchtbericht. April 2004. Mai
2005
2
Nicholson K, Balster R.
GHB – a new and novel drug of abuse.
Drug Alcohol Depend.
2001;
63
1-22
3
Halkitis P N, Palamar J J, Mukherjee P P.
Poly-club-drug use among gay and bisexual men – A longitudinal analysis.
Drug Alcohol Depend.
2007;
89
153-160
4
McDaniel C, Miotto K A.
Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal – five case studies.
J Psychoactive Drugs.
2001;
33 (2)
143-149
5
Bennett W R, Wilson L G, Roy-Byrne P P.
Gamma-hydroxybutyric acid (GHB) withdrawal: a case report.
J Psychoactive Drugs.
2007;
39
293-296
6
Liechti M E. et al .
Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicitiy and concomitant
drug and alcohol use.
Drug Alcohol Depend.
2005;
81
232-326
7
Andresen H. et al .
Liquid Ecstasy – ein relevantes Drogenproblem.
Dtsch Ärztebl.
2008;
105 (36)
599-603
8
Sumnall H R. et al .
Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB).
Drug Alcohol Depend.
2008;
1
286-290
9
Nimmerrichter A, Walter H, Gutierrez-Lobos K E. et al .
Double-blind controlled trial of γ-Hydroxybutyrate and Clomethiazole in the treatment
of alcohol withdrawal.
Alcohol Alcohol.
2001;
37
67-73
10
Kim S Y. et al .
High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users.
Am J Drug Alcohol Abuse.
2007;
33
429-438
11
Wrase J. et al .
Serotonergic dysfunction – brain imaging and behavioral correlates.
Cogn Affect Behav Neurosci.
2006;
6
53-61
12
Abanades S. et al .
Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol
in club drug users.
J Clin Psychopharmacol.
2007;
27
625-638
13
Trendelenburg G, Ströhle A.
Gamma-hydroxybutyrate – a neurotransmitter, medicine, and drug.
Nervenarzt.
2005;
76
832-838
14
Kim S. et al .
Systematic assessment of gamma hydroxybutyrate (GHB) effects during and after acute
intoxication.
Am J Addict.
2008;
17 (4)
312-318
15
McDonough M. et al .
Clinical features and management of gamma-hydroxybutyrate withdrawal-a review.
Drug Alcohol Depend.
2004;
75
3-9
16
Sivilotti M. et al .
Pentobarbital for severe gamma-butyrolactone withdrawal.
Ann Emerg Med.
2001;
38 (6)
660-665
Dr. med. Christoph Richter, MBA
Vivantes Wenckebach-Klinikum, Klinik für Psychiatrie, Psychotherapie und Psychosomatik
– Gerontopsychiatrie
Wenckebachstraße 23
12099 Berlin
Email: ch.richter@charite.de